As Interleukin-17 (IL-17) sanctions enter the primary biological formulation benefit range for psoriasis arthritis, they will compete in earnest with TNF-α inhibitors. Cosentyx (Secukinumab) of Novartis expanded health insurance benefits from psoriasis arthritis to primary biological sanctions on the 1st. Cosentyx can be used if it meets certain conditions among active and progressive arthritis patients who are not effective in treating two or more types of DMARDs or who are difficult to treat due to side effects. The condition is for patients with three or more compressed joints and three or more edema joints.

Previously, IL-17 regulations were paid only when TNF-α inhibitors were used first and u